TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16675705
Drug: Plain polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain polysaccharide vaccine
Study: 15573657
Drug: 0.5‐mg/kg‐body weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg/kg‐body weight midazolam mixed in strawberry syrup via the oral‐transmucosal route
Study: 15573657
Drug: Syrup diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup diluted with normal saline
Study: 9625287
Drug: Acarbose 25
Normalized name: acarbose 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 25 mg t.i.d.
Study: 9625287
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg t.i.d.
Study: 9625287
Drug: Acarbose 200
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 200 mg t.i.d.
Study: 28580833
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (500 mg, 3 times a day for 2 weeks)
Study: 28580833
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch supplement, 500 mg)
Study: 19030909
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose (2 g) of n-3 PUFA
Study: 19030909
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (6.6 g) of n-3 PUFA
Study: 11401423
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline (PTX) with 100 mg carbamazepine (CBZ) at 22:00 h
Study: 11401423
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg carbamazepine (CBZ) alone at 22:00 h
Study: 11401423
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline (PTX) with 100 mg carbamazepine (CBZ) at 10:00 h
Study: 11401423
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg carbamazepine (CBZ) alone at 10:00 h
Study: 9563208
Drug: Sumatriptan 25
Normalized name: sumatriptan 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 25 mg and 50 mg
Study: 7517103
Drug: Individual/Direct therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual/Direct therapy
Study: 7517103
Drug: Group/Consultation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group/Consultation therapy
Study: 28888268
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25mg once daily
Study: 28888268
Drug: Chlorthalidone 25mg
Normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25mg once daily
Study: 25600720
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg/day (decreased by 100 mg every 5 days after the first 5 days)
Study: 25600720
Drug: Prednisone 75
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 75 mg/day (tapered off every 5 days after the first 5 days)
Study: 22179922
Drug: SBC Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBC Group (15 mcg clonidine added to bupivacaine 2.5 mg and sufentanil 5 mcg)
Study: 22179922
Drug: SB Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB Group (bupivacaine 2.5 mg and sufentanil 5 mcg)
Study: 16794456
Drug: High-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol cocoa beverage (446 mg of total flavanols)
Study: 16794456
Drug: Low-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol cocoa beverage (43 mg of total flavanols)
Study: 11074900
Drug: Oral fluconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluconazole, 400 mg/d
Study: 10423939
Drug: Itraconazole, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, 200 mg twice daily
Study: 4073078
Drug: Ticarcillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin plus clavulanic acid (3.1 g every six hours via intravenous infusion)
Study: 4073078
Drug: Moxalactam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (2.0 g every eight hours via intravenous infusion)
Study: 30957444
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy and speech rehabilitation exercises (control group)
Study: 26010037
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections with corticosteroid plus lidocaine
Study: 26010037
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections with lidocaine alone
Study: 21672339
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus rosiglitazone (4 mg once daily, orally)
Study: 16433920
Drug: Budesonide/formoterol (320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (320/9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes, total dose 1280/36 microg)
Study: 16433920
Drug: Formoterol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes, total dose 36 microg)
Study: 16433920
Drug: Budesonide/formoterol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol and Formoterol (both treatments)
Study: 14973093
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg once daily) plus high-selenium baker's yeast (200 microg once daily)
Study: 14973093
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg once daily) plus placebo
Study: 8175445
Drug: lonidamine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonidamine (450 mg p.o. in three divided daily doses)
Study: 3364627
Drug: Budesonide (nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (nasal spray, 400 micrograms/d)
Study: 3364627
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (i.m. injection of 80 mg)
Study: 24073529
Drug: 500 microg-F/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg-F/g with 0.25%CaGP (500 CaGP)
Study: 24073529
Drug: 1,100 microg-F/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100 microg-F/g (1,100) dentifrice
Study: 24073529
Drug: 500 microg-F/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg-F/g (500) dentifrice
Study: 22020609
Drug: Local retropharyngeal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local retropharyngeal steroid (triamcinolone and morcellized collagen sponge)
Study: 22020609
Drug: Local retropharyngeal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local retropharyngeal steroid
Study: 9209176
Drug: Very-low-energy diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-energy diet with increased iron content (27 mg/d)
Study: 9209176
Drug: Very-low-energy diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-energy diet with recommended dietary allowance of iron (18 mg/d)
Study: 8491505
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/day for 7 days
Study: 3030678
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg topically administered beclomethasone dipropionate (BDP)
Study: 3030678
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg betamethasone phosphate (BMT)
Study: 17089229
Drug: Ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.4 mg/kg before incision
Study: 17089229
Drug: Saline before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline before incision, Ketamine 0.4 mg/kg after incision
Study: 9252161
Drug: Ribavirin 600
Normalized name: ribavirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 600 mg given orally twice daily for 36 weeks
Study: 2891285
Drug: Ionic contrast
Normalized name: IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic contrast agent (sodium meglumine diatrizoate)
Study: 2891285
Drug: Nonionic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic contrast agent (iopamidol)
Study: 29476444
Drug: Upward dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upward dose titration of pregabalin
Study: 29476444
Drug: No upward
Approvals — FDA: no, EMA: no, PMDA: no
Description: No upward dose titration (inadequately titrated patients)
Study: 25371633
Drug: Intravitreal Ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Ranibizumab followed by grid laser treatment (Group 1)
Study: 25371633
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab followed by grid laser treatment (Group 2)
Study: 20925997
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with clomiphene citrate (CC) and human menopausal gonadotrophin (HMG)
Study: 20925997
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with clomiphene citrate (CC) and human menopausal gonadotrophin (HMG)
Study: 11954953
Drug: Propranolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.2 mg/kg, n=9)
Study: 9892882
Drug: THC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (10 mg/m2 of body surface area)
Study: 7740291
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASA orally daily (Group A)
Study: 6586277
Drug: AMSA Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMSA Regimen I (120 mg/m2/day for 5 days)
Study: 6586277
Drug: AMSA Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMSA Regimen II (60 mg/m2/day for 10 days)
Study: 30565741
Drug: Zoledronate-coated implant
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate-coated implant
Study: 30565741
Drug: Uncoated implant
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated implant (Control)
Study: 21326328
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy (AT)
Study: 9516597
Drug: Dose-dense paclitaxel-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense paclitaxel-containing therapy (A->T->C regimen)
Study: 7827298
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation (300 mg zinc aspartate, equal to 60 mg elemental zinc per day) for 4 weeks
Study: 25834076
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Group 1)
Study: 25834076
Drug: Regular, ongoing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular, ongoing therapy (Group 3)
Study: 25834076
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (Group 2)
Study: 23833857
Drug: Group LVHC:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LVHC: 0.5 ml/kg bupivacaine 0.375% (1.875 mg/kg)
Study: 23833857
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 1 ml/kg bupivacaine 0.25% (2.5 mg/kg)
Study: 21079463
Drug: anesthetic spray
Normalized name: Americaine 20% Topical Anesthetic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: anesthetic spray
Study: 21079463
Drug: placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo spray
Study: 21079463
Drug: anesthetic intradermal
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: anesthetic intradermal injection
Study: 21079463
Drug: placebo intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intradermal injection
Study: 21079463
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group with no local anesthetic agent
Study: 15082697
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated equine estrogen (CEE)
Study: 8843494
Drug: Inositol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (6 gm daily)
Study: 3865493
Drug: Cefaclor 20
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 20 mg/kg body weight b.i.d. for 10 days
Study: 3865493
Drug: Cefaclor treatment
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor treatment
Study: 30930801
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy (n = 71)
Study: 30930801
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n = 71)
Study: 24518774
Drug: Statin drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drug use
Study: 16953394
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride at a daily dose of 1,500 mg for 12 weeks along with conventional medication
Study: 16953394
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks along with conventional medication
Study: 12398260
Drug: Modafinil 50
Normalized name: armodafinil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 50 mg x 24 h(‐1)
Study: 12398260
Drug: Modafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 150 mg x 24 h(‐1)
Study: 12398260
Drug: Modafinil 300
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 300 mg x 24 h(‐1)
Study: 9915885
Drug: SC-FOS 10
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC-FOS 10 g/d
Study: 9915885
Drug: SC-FOS 20
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC-FOS 20 g/d
Study: 9915885
Drug: SC-FOS 0
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC-FOS 0 g/d (Control)
Study: 9915885
Drug: SC-FOS 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-FOS 2.5 g/d (Control)
Study: 9915885
Drug: SC-FOS 5
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC-FOS 5 g/d (Control)
Study: 7766747
Drug: Bisacodyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl (10 mg)
Study: 7766747
Drug: Lactose (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (45 g)
Study: 38177
Drug: Prednisone (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (high-dose suppressive therapy)
Study: 38177
Drug: Prednisone (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (prophylactic dose)
Study: 38177
Drug: Sulfasalazine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (high dose)
Study: 38177
Drug: Sulfasalazine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (low dose)
Study: 8392345
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparins (LMWH) and Unfractionated heparin (UFH)
Study: 30871639
Drug: lambda‐cyhalothrin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: lambda‐cyhalothrin with pheromone + residual insecticide spray (PI)
Study: 29534330
Drug: Liquid micelles
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid micelles (500 mg vineatrol, 30 mg trans-resveratrol, 75 mg trans-ε-viniferin)
Study: 29534330
Drug: Native powder
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native powder (500 mg vineatrol, 30 mg trans-resveratrol, 75 mg trans-ε-viniferin)
Study: 27137199
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 international units)
Study: 23434570
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week plus methotrexate 7.5 mg/week (increased to 20 mg/week within 2 months) and intra-articular triamcinolone
Study: 10365000
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (group Cl, n = 46)
Study: 10365000
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (group Cl)
Study: 7554701
Drug: 2400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/day felbamate
Study: 7261663
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical thrombin)
Study: 30629046
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg body mass)
Study: 23812464
Drug: Ibandronate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (150 mg orally every month)
Study: 17725176
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg probenecid 3 times daily for 2 days
Study: 9764982
Drug: Alpha-interferon plus
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-interferon plus ofloxacin (600 mg daily)
Study: 9764982
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (alpha-interferon plus ofloxacin)
Study: 7844205
Drug: Low-dose step-down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose step-down hormone replacement therapy (HRT)
Study: 3042355
Drug: Urapidil (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (combination therapy)
Study: 3042355
Drug: Prazosin (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (combination therapy)
Study: 29945395
Drug: Huazhuo Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huazhuo Jiedu formula, 1 dose/day for 6 months
Study: 22828090
Drug: Aliskiren/amlodipine/HCT 150/5/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine/HCT 150/5/12.5 mg (week 4)
Study: 22828090
Drug: Aliskiren/amlodipine/HCT 300/10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine/HCT 300/10/25 mg (week 8)
Study: 22828090
Drug: Aliskiren/amlodipine/HCT 150/5/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine/HCT 150/5/12.5 mg (week 2)
Study: 22828090
Drug: Dual combinations
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combinations (aliskiren/amlodipine 150/5 mg, aliskiren/HCT 150/12.5 mg, amlodipine/HCT 5/12.5 mg)
Study: 22828090
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (aliskiren/amlodipine/HCT)
Study: 19765266
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor (Control)
Study: 18348746
Drug: r-hLH/r-hFSH (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hLH/r-hFSH (fixed combination)
Study: 15888156
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x weekly treatment
Study: 15888156
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x weekly treatment
Study: 15888156
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x weekly treatment
Study: 10353862
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg/day for 4 weeks
Study: 8943671
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin 120 mg/m2 and etoposide 100 mg/m2 i.v. for 3 days, every fourth week) followed by radiotherapy (56 Gy to the chest)
Study: 29165598
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg)
Study: 26475347
Drug: EMLA (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (local anesthetic cream)
Study: 24172652
Drug: Antibiotic pomade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic pomade with bandage (control)
Study: 23109694
Drug: Lanreotide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (30 mg injection)
Study: 17963528
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mild gestational diabetes mellitus (dietary advice, blood glucose monitoring, insulin therapy as needed)
Study: 12093058
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amiodarone (200 mg/day)
Study: 9811284
Drug: Hydrogel moist
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel moist wound dressing (Elasto-gel)
Study: 9811284
Drug: Breast shells
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast shells and lanolin cream
Study: 7658603
Drug: Soy oligosaccharide
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy oligosaccharide fiber (75 g/L)
Study: 7658603
Drug: Soy polysaccharide
Normalized name: Soy polysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy polysaccharide fiber (20 g/L)
Study: 7658603
Drug: Oat fiber
Normalized name: Oat fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat fiber (15 g/L)
Study: 2704504
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (Premarin) + 5 mg medroxyprogesterone acetate (Provera)